CAR-T cells are specialized immune cells genetically modified to recognize and attack cancer cells. Researchers at Nagoya ...

Gut bacteria produce metabolites that influence drug metabolism and affect immune cell function, potentially enhancing or ...

Engineering chimeric antigen receptor (CAR) with intracellular fragment of CTLA-4 enhances CAR-T antitumor activity Cellinfinity has exclusively licensed the CTLA-4 tail technology for development of ...

Chimeric antigen receptor (CAR) therapies utilize engineered receptors that are able to redirect immune cells to identify and destroy cancer cells that express a specific antigen. At present, CAR ...

A novel immunotherapy tool has emerged in the last ten years. T cells engineered to express chimeric antigen receptors, commonly known as CAR T cells, have demonstrated the ability to help ...

A group of researchers at Children's Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an "off-the-shelf" chimeric antigen receptor T-cell (CART ...

After infusion, CAR T cells leave the blood and travel to sites of tumor, where they identify and kill tumor cells. This can trigger extensive proliferation of CAR T cells and the release of tumor ...

Chimeric antigen receptor–modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease. A total of 30 children ...